EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)

Xiuning Le iD, Jyoti D Patel iD, Elaine Shum iD, Christina Baik, Rachel E Sanborn iD, Catherine A Shu iD, Chul Kim iD, Mary Jo Fidler, Richard Hall iD, Yasir Y Elamin iD, Janet Tu iD, George Blumenschein und 18 weitere

Journal of Clinical Oncology · 2025-02 · 43 (4) · 403-411

DOI: 10.1200/jco.24.00533 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025-02. Verfasst von Xiuning Le und 29 weiteren Autor:innen. Beteiligte Einrichtung: UT MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Preclinical studies demonstrated that dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways delay the emergence of resistance to EGFR tyrosine kinase inhibitors (TKIs), and in trials with first-generation EGFR TKIs, the combination of EGFR VEGF pathway inhibitors prolonged progression-free survival (PFS). METHODS The RAMOSE trial (ClinicalTrials.gov identifier: NCT03909334 , HCRN LUN-18-335) is a randomized, open-label multicenter phase II study comparing osimertinib with ramucirumab (arm A) to osimertinib (arm B) for initial treatment of metastatic EGFR -mutant non–small cell lung cancer (NSCLC) with 2:1 random assignment. The primary end point is PFS for evaluable patients; secondary end points include objective response rates (ORRs), disease control rate (DCR), overall survival, and safety. The stratification criteria were EGFR mutation type and the presence of CNS metastasis. RESULTS At data cutoff on August 29, 2023, 160 patients consented, 147 patients received treatment, and 139 patients were evaluable with at least one scan. In this preplanned interim analysis, the median follow-up was 16.6 months. Among the evaluable patients, 57 PFS events occurred. The median PFS was 24.8 (A) versus 15.6 (B) months (hazard ratio, 0.55 [95% CI, 0.32 to 0.93]; log-rank P = .023), 12-month PFS rate was 76.7% (A) versus 61.9% (B; P = .026). No significant difference was observed in the ORRs and DCRs between arms. Any-grade (G) adverse events (AEs) occurred in 100% (A) and 98% (B) of patients, with no G5 treatment-related AE (TRAE), one G4 TRAE (hyponatremia, A), and 53% (A) versus 41% (B) G3 TRAEs. AE-related discontinuation occurred in 13 patients (9.7% in A and 8.7% in B). The safety profile was in line with known safety of each drug. CONCLUSION Ramucirumab plus osimertinib significantly prolonged PFS compared with osimertinib alone in patients with TKI-naïve EGFR -mutant NSCLC. The combination is safe and well tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesAniline CompoundsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedErbB ReceptorsMutationProgression-Free SurvivalRamucirumabTyrosine Kinase InhibitorsIndolesPyrimidines

Substanzen

AcrylamidesAniline CompoundsAntibodies, Monoclonal, HumanizedEGFR protein, humanErbB ReceptorsosimertinibRamucirumabTyrosine Kinase InhibitorsIndolesPyrimidines

Autor:innen und Institutionen

  • UT MD Anderson Cancer Center, Houston, TX.
  • Northwestern University, Chicago, IL.
  • New York University Cancer Center, New York, NY.
  • University of Washington, Seattle, WA.
  • Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR.
  • Columbia University Irving Medical Center, New York, NY.

ORCID-Profile: Xiuning Le, Jyoti D Patel, Elaine Shum, Rachel E Sanborn, Catherine A Shu, Chul Kim, Richard Hall, Yasir Y Elamin, Janet Tu, Jianjun Zhang, Don Gibbons, Nisha A Mohindra, Young Chae, Yanis Boumber, Joshua Sabari, Rafael Santana-Davila, Ben Creelan, Bruna Pellini, Tawee Tanvetyanon, Mike Hernandez, Andreas Saltos, John V Heymach

Zitieren

APA

Le, X., Patel, J. D., Shum, E., Baik, C., Sanborn, R. E., Shu, C. A., Kim, C., Fidler, M. J., Hall, R., Elamin, Y. Y., Tu, J., Blumenschein, G., Zhang, J., Gibbons, D., Gay, C., Mohindra, N. A., Chae, Y., Boumber, Y., Sabari, J., …, & Heymach, J. V. (2025). A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial). Journal of Clinical Oncology, 43(4), 403-411. https://doi.org/10.1200/jco.24.00533

Vancouver

Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, et al. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial). Journal of Clinical Oncology. 2025;43(4):403-411. doi:10.1200/jco.24.00533

BibTeX
@article{Le2025,
  author = {Le, Xiuning and Patel, Jyoti D and Shum, Elaine and Baik, Christina and Sanborn, Rachel E and Shu, Catherine A and Kim, Chul and Fidler, Mary Jo and Hall, Richard and Elamin, Yasir Y and Tu, Janet and Blumenschein, George and Zhang, Jianjun and Gibbons, Don and Gay, Carl and Mohindra, Nisha A and Chae, Young and Boumber, Yanis and Sabari, Joshua and Santana-Davila, Rafael and Rogosin, Shane and Herzberg, Benjamin and Creelan, Ben and Pellini, Bruna and Tanvetyanon, Tawee and Heeke, Simon and Hernandez, Mike and Gray, Jhanelle E and Saltos, Andreas and Heymach, John V},
  title = {A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {4},
  pages = {403--411},
  doi = {10.1200/jco.24.00533}
}
Kostenlos starten →